Checkmate Pharmaceuticals Inc. (CMPI): Price and Financial Metrics


Checkmate Pharmaceuticals Inc. (CMPI): $6.91

0.14 (+2.07%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CMPI Stock Price Chart Interactive Chart >

Price chart for CMPI

CMPI Price/Volume Stats

Current price $6.91 52-week high $23.10
Prev. close $6.77 52-week low $5.84
Day low $6.80 Volume 118,800
Day high $7.15 Avg. volume 46,849
50-day MA $7.28 Dividend yield N/A
200-day MA $11.74 Market Cap 149.44M

Checkmate Pharmaceuticals Inc. (CMPI) Company Bio


Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. It specializes in the field of CpG oligonucleotides. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA.


CMPI Latest News Stream


Event/Time News Detail
Loading, please wait...

CMPI Latest Social Stream


Loading social stream, please wait...

View Full CMPI Social Stream

Latest CMPI News From Around the Web

Below are the latest news stories about Checkmate Pharmaceuticals Inc that investors may wish to consider to help them evaluate CMPI as an investment opportunity.

Checkmate Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference

CAMBRIDGE, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Barry Labinger, CEO, will present at the Jefferies Virtual Healthcare Conference from 2:00-2:25pm ET on Tuesday, June 1, 2021. Checkmate will also host 1x1 investor meetings during the conference. A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the Checkmate website. An archived copy of the webcast will be available on the Checkmate website for approximately 30 days after the event. About Checkmate Pharmaceuticals Checkmate Pharmaceuticals is a c...

Yahoo | May 20, 2021

Checkmate Pharmaceuticals Announces Clinical Supply Agreement with Regeneron to Evaluate Vidutolimod (CMP-001) in Combination with Libtayo® (cemiplimab)

CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the development program expansion of vidutolimod (CMP-001) into non-melanoma skin cancers in combination with Libtayo® (cemiplimab) under a clinical supply agreement with Regeneron Pharmaceuticals, Inc. (“Regeneron”). Vidutolimod is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component. Cemiplimab is a PD-1 blocking antibody being jointly developed by Regeneron and Sanofi. Checkmate and Regeneron will col...

Yahoo | May 10, 2021

Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Potential Registration Trial of Vidutolimod (CMP-001) in Patients with Anti-PD-1 Refractory Advanced Melanoma

CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that patient dosing was initiated in a Phase 2 trial intended to assess the efficacy and safety of vidutolimod (CMP-001) in combination with nivolumab for the treatment of patients with anti-PD-1 refractory advanced melanoma. Vidutolimod is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component. Checkmate previously announced initiation of dosing in patients in an additional trial which is evaluating the e...

Yahoo | May 4, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting off the week right with a collection of the biggest pre-market stock movers for Monday that investors need to know about.

William White on InvestorPlace | May 3, 2021

Checkmate Pharmaceuticals Releases Clinical Data For Vidutolimod And Pembrolizumab Combo

Clinical-stage biotechnology company Checkmate Pharmaceuticals Inc. reported data from its Phase 1b trial evaluating the combination of vidutolimod and pembrolizumab for the treatment of advanced anti-PD-1 refractory melanoma. Checkmate Pharmaceuticals' (CMPI) product candidate vidutolimod is delivered as a biologic virus-like particle. It is designed to trigger the patient’s innate immune system to target tumors in combination with other therapies.  Dr.

Kailas Salunkhe on TipRanks | April 12, 2021

Read More 'CMPI' Stories Here

CMPI Price Returns

1-mo 2.52%
3-mo -53.28%
6-mo -53.93%
1-year N/A
3-year N/A
5-year N/A
YTD -52.64%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8075 seconds.